Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:angiogenesis inhibitor
go back to main search page
Accession:CHEBI:48422 term browser browse the term
Definition:An agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
Synonyms:related_synonym: angiogenesis antagonist;   angiostatic agents;   anti-angiogenic agent
 alt_id: CHEBI:67170
 xref: Wikipedia:Angiogenesis_inhibitor


show annotations for term's descendants           Sort by:
 





Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19801
    role 19747
      application 19395
        pharmaceutical 19266
          drug 19266
            angiogenesis inhibitor 8338
              (-)-antofine 2
              (-)-matairesinol + 0
              (-)-voacangine 0
              (1R,2S,3S,4S)-4-formyl-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexyl (2E)-3-(4-methoxyphenyl)acrylate 0
              (1S,2S,3S)-3-methoxy-2-[(2E)-6-methylhept-2-en-2-yl]-4-oxocyclohexanecarbaldehyde + 0
              (2S,3S,4S)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]-4-(trifluoroacetyl)cyclohexanone 0
              (2S,3S,4S)-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (2S,3S,4S)-4-(hydroxymethyl)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (2S,3S,4S)-4-acetyl-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid 0
              3PO 0
              GP369 0
              JQ1 0
              N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
              O-(chloroacetylcarbamoyl)fumagillol 10
              PD-166866 + 21
              SB220025 0
              SH-11037 0
              SU4312 0
              ageladine A 4
              amentoflavone + 28
              ascochlorin 0
              ascofuranone 0
              cafestol 21
              capsiate 7
              crenolanib 0
              disulfiram 567
              epoxytwinol A 0
              fumagillin + 5
              herbacetin 5
              kahweol 31
              lenalidomide 29
              leucosesterlactone 0
              leucosesterterpenone 0
              linifanib 0
              luminespib 0
              lupulone 0
              luteolin + 171
              meso-tetrakis(N-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate) 0
              meso-tetrakis(N-methyl-4-pyridyl)porphine(4+) + 1
              nintedanib 1
              nintedanib esylate 0
              oridonin 38
              pomalidomide 44
              quininib 0
              quininib hydrochloride 0
              rifampicin + 376
              sorafenib + 155
              sunitinib + 5778
              suramin 31
              tamoxifen + 3236
              tamoxifen citrate 0
              thalidomide + 451
              toluquinol 0
              vatalanib + 2
              vatalanib succinate 0
              wogonin + 52
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.